glp-1 obesity drug news Alarming rise in weight loss overdoses glp-1 news today obesity drug
Description
Chappuis, Genve (Mdecine des voyages)
Pharmaceutical companies stand to make a lot of money from these drugs
Lancet 372(9645):12401250 Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
It's been clinically shown to improve post-meal blood sugar in type 2 diabetes, though research is limited
The Glucagon Like Peptide-1 (GLP-1) receptor agonist, exenatide, has been shown to significantly reduce ICP in IIH, therefore this study aimed to determine the effects of exenatide on cognition in IIH
Available from: [Google Scholar] 27.Damms-Machado A., Weser G., Bischoff S.C
